Vitamin K antagonists (VKAs) are the standard of care for patients with rheumatic heart disease related atrial fibrillation. Rivaroxaban is an anticoagulant used to treat and prevent blood clots. In this touchCARDIO interview, we speak with Professor Ganesan Karthikeyan (All India Institute of Medical Sciences, New Delhi, India) to discuss the risk factors of stroke in patients with rheumatic heart disease and the potential benefits of rivaroxaban over VKAs.
The abstract entitled ‘INVICTUS – Rivaroxaban versus VKA for rheumatic atrial fibrillation’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What factors influence stroke risk in patients with rheumatic heart disease? (0:25)
- What are the potential advantages of rivaroxaban over vitamin K antagonists (VKAs) for prevention of stroke or systemic embolism in patients with rheumatic valvular heart disease? (2:04)
Disclosures: Ganesan Karthikeyan has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Share this Video
Related Videos In Cardiovascular Disease
John Forrest, ACC 2023: Evolut low risk trial, transcatheter versus surgical aortic valve replacement in patients at low surgical risk
The Evolut low risk trial aimed to compare transcatheter versus surgical aortic valve replacement in patients who were at low risk for surgery. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to discuss the eligibility criteria, the key findings and the outlook for […]
John Forrest, ACC 2023: The treatment paradigm for patients with aortic stenosis
The treatment paradigm for aortic stenosis has developed dramatically in the past decade. In this touchCARDIO interview, we speak with Dr John Forrest (Yale New Haven Hospital, Yale University, New Haven, CT, USA) to outline and discuss the developments. Dr Forrest presented an abstract entitled ‘Transcatheter Versus Surgical Aortic Valve Replacement In Aortic Stenosis Patients […]
Steven Nissen, ACC 2023: Lipid-lowering therapies – current and future options
Many lipid-lowering therapies exist, such as statins to manage and reduce lipid levels. While statins are the most commonly used medication, some patients may need additional interventions to lower their LDL cholesterol levels. In this touchCARDIO interview, we speak with Prof. Steven Nissen (Cleveland Clinic, Cleveland, OH, USA) to explore current and developing novel lipid-lowering […]